CENCORA, INC. for CENCORA, INC.
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Repeal of LIFO (last in, first out).
| Lobbyist | Covered position, as disclosed |
|---|---|
| JASON R. MONEY | — |
| RITA E NORTON | — |
| BRADFORD TALLAMY | — |
Medicare/Medicaid MMM
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts. CMS Medicare Part B Drug Payment Model. H.R. 1934, The Cancer Care Payment Reform Act of 2015.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JASON R. MONEY | — |
| RITA E NORTON | — |
| BRADFORD TALLAMY | — |
Pharmacy PHA
H.R.471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JASON R. MONEY | — |
| RITA E NORTON | — |
| BRADFORD TALLAMY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.